{"id":"rbt-1","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RBT-1 works by inhibiting the angiotensin-converting enzyme (ACE), which is a key component of the renin-angiotensin system. This leads to decreased levels of angiotensin II, a potent vasoconstrictor, resulting in vasodilation and reduced blood pressure.","oneSentence":"RBT-1 is a small molecule that targets the renin-angiotensin system to treat hypertension.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:21.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT03893799","phase":"PHASE1","title":"A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease","status":"COMPLETED","sponsor":"Renibus Therapeutics, Inc.","startDate":"2019-08-27","conditions":"Healthy Volunteers, Chronic Kidney Disease","enrollment":54},{"nctId":"NCT06092970","phase":"","title":"An Evaluation of Patient Reported Outcomes and Clinical Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Renibus Therapeutics, Inc.","startDate":"2023-10-16","conditions":"Post-Operative Complications in Cardiac Surgery","enrollment":379},{"nctId":"NCT06021457","phase":"PHASE3","title":"Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Renibus Therapeutics, Inc.","startDate":"2023-10-17","conditions":"Post-Operative Complications in Cardiac Surgery","enrollment":454},{"nctId":"NCT04564833","phase":"PHASE2","title":"Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery","status":"COMPLETED","sponsor":"Renibus Therapeutics, Inc.","startDate":"2021-08-04","conditions":"AKI","enrollment":152},{"nctId":"NCT03630029","phase":"PHASE1","title":"RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD","status":"WITHDRAWN","sponsor":"Renibus Therapeutics, Inc.","startDate":"2018-09-15","conditions":"Acute Kidney Injury","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RBT-1","genericName":"RBT-1","companyName":"Renibus Therapeutics, Inc.","companyId":"renibus-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RBT-1 is a treatment being studied in a Phase 1b clinical trial for conditions such as Acute Kidney Injury, Post-Operative Complications in Cardiac Surgery, and Chronic Kidney Disease. The trial is being conducted by Renibus Therapeutics, Inc. to assess the safety and efficacy of RBT-1 in healthy volunteers and subjects with Chronic Kidney Disease Stage 3b-4.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}